Cover Image
市場調查報告書

Eylea(糖尿病的微血管併發症)- 預測與市場分析

Eylea (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 294517
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
Eylea(糖尿病的微血管併發症)- 預測與市場分析 Eylea (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
出版日期: 2014年10月31日 內容資訊: 英文 87 Pages
簡介

糖尿病的微血管併發症(糖尿病腎病變·視網膜病變·神經病變)整體市場,面臨主要7個國家(美國、歐洲5個國家、日本)極高水準的未滿足需求。在帶來莫大可能性之下同時也面臨過少開發平台這個世界性障礙。糖尿病視網膜病變的市場的新抗VEGF(血管內皮生長因子)療法正在迅速發展,並展現出強力成長。同時糖尿病腎病變·神經病變市場也在學名藥的競爭下,企業數正在增加。

本報告提供由VEGF結合部分而成的融合蛋白──Eylea的治療方法調查分析,提供疾病概要和治療指南,競爭情形,產品資訊,主要國家的銷售額預測等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 糖尿病腎病變
    • 糖尿病視網膜病變
    • 糖尿病神經病變
  • 預測
  • QOL
  • 症狀

第4章 疾病的管理

  • 治療概要
    • 診斷和詢問
    • 篩檢
    • 治療指南

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估

第6章 機會及未滿足需求

  • 概要
  • 未滿足需求
  • 未滿足需求的差距分析
  • 機會

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物

第8章 Eylea(aflibercept)

  • 概要
  • 功效
  • 安全性
  • 給藥·處方
  • 潛在的臨床性地位
  • 潛在的商業性地位
  • 價格與回本
  • SWOT分析
  • 預測

第9章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC482DFR

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Eylea (aflibercept) is a recombinant fusion protein co-developed by Regeneron and Bayer AG. Eylea acts as a VEGF inhibitor and is approved for the treatment of wAMD and ME-CRVO in all 7MM, and for DME in the US and EU. The developers are also attempting to gain approval for Eylea for DME in Japan, and for ME-BRVO throughout in the EU and Japan.

Scope

  • Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Eylea including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Eylea for the top seven countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Eylea performance.
  • Obtain sales forecast for Eylea from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Disease Overview

  • 3.1. Macular Degeneration Overview
    • 3.1.1. Etiology and Pathophysiology
    • 3.1.2. Classification
    • 3.1.3. Symptoms and Diagnosis
  • 3.2. Macular Edema Overview
    • 3.2.1. Etiology and Pathophysiology
    • 3.2.2. Classification
    • 3.2.3. Symptoms and Diagnosis

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Macular Edema Diagnosis
    • 4.1.2. Macular Degeneration Diagnosis
    • 4.1.3. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.4. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Eylea (aflibercept)

  • 6.1. Overview
  • 6.2. Efficacy - Macular Degeneration
  • 6.3. Efficacy - Macular Edema
  • 6.4. Safety

6.5. SWOT Analysis

  • 6.6. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed ME and AMD Patients
    • 7.4.2. Percentage of Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
  • 7.5. Primary Research - KOLs Interviewed for this Report
  • 7.6. Primary Research - High-Prescribers Survey
  • 7.7. About the Authors
    • 7.7.1. Analyst
    • 7.7.2. Therapy Area Director
    • 7.7.3. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: ARM System Classification of AMD
  • Table 2: Symptoms of AMD
  • Table 3: National and International Treatment Guidelines for ME and AMD
  • Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013
  • Table 5: Leading Treatments for ME and AMD, 2014
  • Table 6: Approval Dates for Eylea
  • Table 7: Product Profile - Eylea
  • Table 8: Eylea - Common Adverse Reactions
  • Table 9: Eylea SWOT Analysis, 2014
  • Table 10: Global Sales Forecast ($m) for Eylea, 2013-2023
  • Table 11: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Anatomy of the Eye and Macula
  • Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD
  • Figure 3: Color Fundus Photographs of Dry and Wet AMD
  • Figure 4: FAF Imaging of GA
  • Figure 5: Imaging of wAMD
  • Figure 6: CMT in DME
  • Figure 7: RVOs (BRVO and CRVO) on an FA
  • Figure 8: Increased CRT in ME-RVO
  • Figure 9: ME Clinical Treatment Flowchart
  • Figure 10: AMD Clinical Treatment Flowchart
  • Figure 11: Eylea's Clinical Development in DME and ME-BRVO
Back to Top